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Abstract
Background/Aim. Bacterial contamination of blood com-
ponents, primarily platelet concentrates (PCs), has been iden-
tified as one of the most frequent infectious complications in
transfusion practice. PC units have a high risk for bacterial
growth/multiplication due to their storage at ambient tem-
perature (20 ± 2°C). Consequences of blood contamination
could be effectively prevented or reduced by pathogen inacti-
vation systems. The aim of this study was to determine the
Mirasol pathogen reduction technology (PRT) system efficacy
in PCs using an artificial bacteria-contamination model.
Methods. According to the ABO blood groups, PC units
(n = 216) were pooled into 54 pools (PC-Ps). PC-Ps were di-
vided into three equal groups, with 18 units in each, designed
for an artificial bacteria-contamination. Briefly, PC-Ps were
contaminated by Staphylococcus epidermidis, Staphylococcus aureus
or Escherichia coli in concentrations 102 to 107 colony forming
units (CFU) per unit. Afterward, PC-Ps were underwent to
inactivation by Mirasol PRT system, using UV ( = 265–370
nm) activated riboflavin (RB). All PC-Ps were assayed by
BacT/Alert Microbial Detection System for CFU quantifica-
tion before and after the Mirasol treatment. Samples from
non-inactivated PC-P units were tested after preparation and
immediately following bacterial contamination. Samples from
Mirasol treated units were quantified for CFUs one hour, 3
days and 5 days after inactivation. Results. A complete inac-
tivation of all bacteria species was obtained at CFU concen-
trations of 102 and 103 per PC-P unit through stor-
age/investigation period. The most effective inactivation (105
CFU per PC-P unit) was obtained in Escherichia coli setting.
Contrary, inactivation of all the three tested bacteria species
was unworkable in concentrations of ≥ 106 CFU per PC-P
unit. Conclusion. Efficient inactivation of investigated bacte-
ria types with a significant CFU depletion in PC-P units was
obtained – 3 Log for all three tested species, and 5 Log for
Escherichia coli. The safety of blood component therapy, pri-
marily the clinical use of PCs can be improved using the Mi-
rasol PRT system.
Key words:
blood platelets; platelet transfusion; bacterial
infections; treatment outcome; riboflavin; ultraviolet
rays.
Apstrakt
Uvod/Cilj. Bakterijska kontaminacija hemoprodukata, pr-
venstveno koncentrovanih trombocita (KT), jedna je od
najčešćih infektivnih komplikacija u transfuzijskoj praksi.
Zbog skladištenja na sobnoj temperaturi (20 ± 2°C), KT
predstavljaju veliki rizik od umnožavanja bakterija. Posledi-
ce bakterijske kontaminacije mogu biti efikasno sprečene ili
smanjene upotrebom sistema za inaktivaciju patogena u raz-
ličitim hemoproduktima. Cilj ovog rada bio je procena efi-
kasnosti Mirasol sistema za redukciju patogena (PRT) u KT
korišćenjem modela arteficijalne bakterijske kontaminacije.
Metode. U skladu sa krvnim grupama ABO, jedinice KT
(n = 216) spojene su u 54 pula (P-KT) koji su bili podeljeni
u tri jednake grupe, u svakoj po 18 jedinica, namenjenih za
arteficijalnu bakterijsku kontaminaciju. Jedinice P-KT bile
su kontaminirane bakterijama Staphylococcus epidermidis,
Staphylococcus aureus i Escherichia coli u koncentracijama od 102
do 107  CFU po jedinici. Potom su P-KT bili podvrgnuti
inaktivaciji sistemom Mirasol PRT, korišćenjem riboflavina
aktiviranog UV zracima ( = 265 – 370 nm). Svi P-KT su
testirani sistemom BacT/Alert Microbial Detection na prisustvo
CFU pre i posle postupka Mirasol. Uzorci iz neinaktivisanih
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posle kontaminacije bakterijama. Uzorci iz jedinica tretiranih
Mirasolom ispitivani su na prisustvo CFU jedan sat, odnos-
no 3 i 5 dana nakon inaktivacije. Rezultati. Tokom perioda
čuvanja/istraživanja postignuta je kompletna inaktivacija
bakterija svih vrsta u koncentracijama od 102 i 103 CFU po
P-KT. Najefikasnija inaktivacija (105 CFU po P-KT) postig-
nuta je pri ispitivanju bakterije Escherichia coli. Nasuprot to-
me, inaktivacija kod sve tri vrste bakterija nije bila efikasna u
koncentracijama bakterija ≥ 106 CFU po P-KT. Zaključak.
Efikasna inaktivacija ispitivanih bakterija sa bitnim smanje-
njem CFU u P-KT – 3 Log postignuta je za sve tri vrste ba-
kterija i 5 Log za bakteriju Escherichia coli. Bezbednost tera-
pije krvnim komponentama, prvenstveno klinička primena
KT, može biti unapređena korišćenjem sistema Mirasol
PRT.
Ključne reči:
trombociti; transfuzija trombocita; infekcija,
bakterijska; lečenje, ishod; vitamin b2; ultravioletni
zraci.
Introduction
The use of various inactivation techniques clearly re-
duces pathogen occurrence in collected blood. The Mirasol
pathogen reduction technology (PRT) system is based on the
treatment by ultraviolet (UV) illuminated/activated ribofla-
vin (RB), resulting in inactivation of white blood cells
(WBC) and pathogens at the molecular level due to irre-
versible photochemically induced damage of nucleic acids.
These photochemical mechanisms inhibit nucleic acid repli-
cation and decrease incidence of potential transfusion side
effects or complications 
1–5.
Generally, the risk of transfusion-associated infections
– applying bacteria contaminated platelet concentrates
(PCs) is about 1,000 times greater than the hazard of trans-
fusion-related HIV, hepatitis C or B virus and human T-
lymphotropic virus transmission 
6, 7. The most important
sources of bacterial contamination of collected blood are
the donor skin 
8–11 or asymptomatic donors – low-level or
transient bacteremia in chronic bacterial infections, as well
as a recovery from a disease 
12–15. Seldom, the source of
bacteria can be a nonsterile equipment for collection or de-
vices for processing of harvested blood units 
16–18. The
prevalence of bacterial contamination is relatively high in
PCs – from 0.14% to 1.41% – since their storage tempera-
ture  (22 ± 2°C)  favors  bacteria  growth/multiplication 
6, 19.
Consequently, PCs are the most common cause of transfu-
sion-associated bacterial morbidity and mortality. How-
ever, the rate of blood contamination is higher than the in-
cidence of bacterial infections because their clinical mani-
festation depends on numerous factors, such as patient's
general condition, antibiotic therapy, quantity and type of
bacteria, etc 
20–22.
Strategies to reduce the risk of transfusion-associated
bacterial infections include superior donor selection 
23, im-
proved preparation and disinfecting of venepunction field 
24–
27, redirecting the initial blood stream into satellite bag at the
start of collection 
25, 26, improved processing procedure safety
and reduced storage time 
28, 29, reevaluation/optimization of
thresholds and criteria for transfusion supportive treatment 
30,
31, as well as the use of different pathogen inactivation sys-
tems 
1, 5–7, 32.
The aim of this study was to evaluate the Mirasol PRT
system efficacy in artificial bacteria-contamination model
and to predict the importance of its application in prevention
of potential infectious complications of PC clinical use.
Methods
The study included 216 units of buffy coat derived PCs;
the volume was 62.4 ± 8 mL in average. The units of PC
were separated from whole blood collected by a CPD/SAGM
quadruple bag system (Macopharma, France) within 6 hours
after donation, using a T-ACE II blood processor (Terumo,
Japan). According to the ABO blood groups, PC units were
pooled into 54 pools (PC-Ps; four PCs per PC-P unit). After
that PC-Ps were divided into three equal groups, with 18 PC-
P units in each (mean PC-P volume was 256.6 ± 14 mL). PC-
Ps were stored at ambient temperature (22 ± 2°C) for 2 hours
and then were filtered using an Imugard III-PL (Terumo, Ja-
pan).
The PC-P units were artificially contaminated by three
different bacteria species. In brief, into the units of the first
PC-P group Staphylococcus epidermidis (isolated from the
skin), in the second group Staphylococcus aureus (ATCC
25923), and in the units of the third group Escherichia coli
(ATCC 25922) were inoculated. The initial bacteria con-
centration for all the three species was 0.5 McF (1.5 × 108
CFU  /  mL). Initial suspensions were diluted (six different
dilutions were applied) and inoculated into the units of PC-P
groups regarding all the three species in the same way.
Therefore, the final counts of inoculated CFUs  were 102
to 107 per PC-P unit.
Before bacterial contamination, samples were taken (1st
sample; sterility control) from the PC-P units and investi-
gated by a BacT/Alert Microbial Detection System (Biom-
erieux, France). After contamination, from PC-P units sam-
ples were taken also to confirm contamination success (2nd
sample; contamination checking). All PC-P units un-
derovment inactivation by the Mirasol PRT system (Caridi-
anBCT, USA) – that is using UV ( = 265 – 370 nm) acti-
vated RB according to the manufacturer's instructions. Con-
cisely, a sterile solution contains RB (500 μmol / L)  in  a
0.9% sodium chloride solution (pH range: 4.0–5.0). A vol-
ume of 35 ± 5 mL of this solution is added to PC-P units to
produce a final concentration 57–60 μmol / L. The illumina-
tor delivers the required UV light dose (6.24 J / mL) to the
contents of an illumination bag (Mirasol Platelet Illumina-
tion/Storage set), based on product volume and measured
flux rate 
3.
The units are then returned to platelets shaker up to the
moment of the investigations that followed. Finally, the sam-
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after the Mirasol inactivation and storage at 20 ± 2C (3rd,
4th and 5th samples) were investigated for CFU units.
Results
The results of the PC-P testing before and after the
contamination with bacteria Staphylococcus epidermidis (six
different concentrations), and after inactivation of pathogens
using the Mirasol PRT system, are presented in Table 1.
The samples of contaminated PC-Ps with Staphylococ-
cus epidermidis in the concentration of 10
4 CFU per PC-P
were also sterile after the Mirasol PRT inactivation process
and during a storage period, while in bacterial concentration
of 10
5 CFU per PC-P, only one PC-P was sterile.
Testing relating to contamination of PC-Ps with bacte-
ria Staphylococcus aureus and bacteria Escherichia coli in
different concentrations is shown in Tables 2 and 3, respec-
tively.
In the samples from PC-Ps contaminated with
Staphylococcus aureus in the concentration of 10
4 CFU
per PC-Ps, we proved the presence of the said bacteria
after the storage period of three and five days (4th and 5th
samples, respectively), despite the negative results of the
first sample taken one hour after the Mirasol PRT inacti-
vation.
The highest degree of pathogen reduction has been
made in PC-Ps contaminated by Escherichia coli inoculation.
In concentrations of bacteria ≤ 10
5 CFU per PC-Ps, the sam-
Table 1
Inactivation efficiency of the Mirasol PRT after platelet concentrates contamination with Staphylococcus epidermidis
Bacteria presence in the sample PC-P number CFU per
PC-P unit initial* contaminated** inactivated–1
 inactivated–2
 inactivated–3

J1004 1000001 Ø + Ø Ø Ø
J1004 1000002 Ø + Ø Ø Ø
J1004 1000003
10
2
Ø+ Ø Ø Ø
J1004 1000004 Ø + Ø Ø Ø
J1004 1000005 Ø + Ø Ø Ø
J1004 1000006
10
3
Ø+ Ø Ø Ø
J1004 1000007 Ø + Ø Ø Ø
J1004 1000008 Ø + Ø Ø Ø
J1004 1000009
10
4
Ø+ Ø Ø Ø
J1004 1000010 Ø + + + +
J1004 1000011 Ø + Ø Ø Ø
J1004 1000012
10
5
Ø+ + + +
J1004 1000013 Ø + + + +
J1004 1000014 Ø + + + +
J1004 1000015
10
6
Ø+ + + +
J1004 1000016 Ø + + + +
J1004 1000017 Ø + + + +
J1004 1000018
10
7
Ø+ + + +
*1st sample – before bacterial contamination; **2nd sample – immediately after bacterial contamination; 
3rd sample – one hour after inactivation;
4th sample – day 3 after inactivation; 
5th sample – day 5 after inactivation.
Table 2
Inactivation efficiency of the Mirasol PRT after platelet concentrations contamination with Staphylococcus aureus
Bacteria presence in the sample PC-P number CFU per
PC-P unit initial* contaminated** inactivated–1
 inactivated–2
 inactivated–3

J1004 1000019 Ø + Ø Ø Ø
J1004 1000020 Ø + Ø Ø Ø
J1004 1000021
10
2
Ø+ Ø Ø Ø
J1004 1000022 Ø + Ø Ø Ø
J1004 1000023 Ø + Ø Ø Ø
J1004 1000024
10
3
Ø+ Ø Ø Ø
J1004 1000025 Ø + Ø + +
J1004 1000026 Ø + Ø Ø Ø
J1004 1000027
10
4
Ø+ Ø Ø +
J1004 1000028 Ø + + + +
J1004 1000029 Ø + + + +
J1004 1000030
10
5
Ø+ Ø + +
J1004 1000031 Ø + + + +
J1004 1000032 Ø + + + +
J1004 1000033
10
6
Ø+ + + +
J1004 1000034 Ø + + + +
J1004 1000035 Ø + + + +
J1004 1000036
10
7
Ø+ + + +
*1st sample – before bacterial contamination; **2nd sample – immediately after bacterial contamination; 
3rd sample – one hour after inactivation;
4th sample – day 3 after inactivation; 
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ples were sterile during the whole storage period. However,
pathogen inactivation was not successful with bacterial con-
centrations  10
6 CFU per PC-Ps.
The results show that all PC-P units (n = 54) were ster-
ile before testing (1st sample), as well as that the contamina-
tion of units by all the three bacteria species in all concentra-
tions – from 10
2 to 10
7 – was confirmed (2nd sample). There
was a complete inactivation of bacteria in concentrations of
10
2 and 10
3 CFU per PC-P (the degree of reduction was 2
and 3 Log) during the storage period (3rd, 4th and 5th sam-
ples) for all the three types of bacteria.
Summarily, in our study using the Mirasol PRT system
bacterial depletion rank was 3–5  Log for all the three of
bacteria species.
Discussion
The bacteria presence in PCs is often the result of their
inadequate removal from the skin of donors (venepunction
field), not diagnosed donor's bacteremia and possible blood
contamination during collection and processing 
33–36. Bacte-
rial contamination of PCs, associated with adverse transfu-
sion reactions showed that most commonly isolated Gram-
positive bacteria from donor's skin (Staphylococcus epider-
midis and Staphylococcus aureus) were found in more than
70% of published cases of sepsis associated with PC transfu-
sion 
6, 35, 37. Contrary to this, some published data showed
that Gram-negative bacterias, such as Escherichia coli,
Pseudomonas aeruginosa, Bacillus cereus and Serratia mar-
cescens are most commonly isolated pathogens in transfu-
sion associated sepsis. Fatal outcome was the result of infec-
tion with Gram-negative bacterias in 63% of cases in com-
parison with 37% of fatal outcome after infections with
Gram-positive bacterias 
6, 35, 37.
To assess the efficacy of bacterial reduction by the Mi-
rasol PRT system, two types of experiments known as “high
spike bacterial titer” and “low spike bacterial titer” tests were
performed 
1. Both methods involve inoculation of the known
number of bacteria before inactivation of pathogens, and
subsequently prove the presence or quantification of re-
maining bacteria (CFU) and calculate degree of their reduc-
tion. The aim of the experiments with high-titer bacteria in-
oculation was to determine the full potential of the Mirasol
PRT system in the terms of reduction of a large number of
bacteria in PCs. Contrary, in studies with inoculation of low,
but clinically significant titer of bacteria, after the Mirasol
inactivation of pathogens (0.5–2 Log CFU per mL), evalua-
tion of PCs usefulness for transfusion was performed using
standard systems to detect contamination during the whole
storage period 
1, 38.
Based on these facts, our pathogen inactivation model
examined the Mirasol treatment efficacy in PCs, previously
contaminated with different bacterial species most frequently
associated with bacterial adverse transfusion complications –
Staphylococcus epidermidis, Staphylococcus aureus and Es-
cherichia coli. Inoculation prepared with a various bacterial
concentrations (range: 10
2 to 10
7 CFU per PC-P unit).
Checking the maximum capacity of the Mirasol PRT system
for the degree of pathogen inactivation was testing by in-
oculation of high bacterial concentrations in the PCs.
Evaluation of the Mirasol efficacy in the prevention of po-
tential infectious complications after transfusion of contami-
nated PC units was performed due to inoculation of lower
bacteria's concentrations – mimicring the conditions regu-
larly seen in clinical practice.
For the period of storage bacteria can growth/multiply
quickly, as in our study with PC-Ps contaminated with
Staphylococcus aureus species in the concentration of
10
4 CFU per PC-P in two PC-Ps. Despite the reduction of
bacteria's number after the Mirasol PRT system inactivation
to undetectable degree (negative result in the 3rd sample),
there was a multiplication of the remaining viable bacteria to
Table 3
Inactivation efficiency of the Mirasol PRT after platelet concentrate contamination with Escherichia coli
Bacteria presence in the sample PC-P number CFU per
PC-P unit initial* contaminated** inactivated–1
 inactivated–2
 inactivated–3

J1004 1000037 Ø + Ø Ø Ø
J1004 1000038 Ø + Ø Ø Ø
J1004 1000039
10
2
Ø+ Ø Ø Ø
J1004 1000040 Ø + Ø Ø Ø
J1004 1000041 Ø + Ø Ø Ø
J1004 1000042
10
3
Ø+ Ø Ø Ø
J1004 1000043 Ø + Ø Ø Ø
J1004 1000044 Ø + Ø Ø Ø
J1004 1000045
10
4
Ø+ Ø Ø Ø
J1004 1000046 Ø + Ø Ø Ø
J1004 1000047 Ø + Ø Ø Ø
J1004 1000048
10
5
Ø+ Ø Ø Ø
J1004 1000049 Ø + + + +
J1004 1000050 Ø + + + +
J1004 1000051
10
6
Ø+ + + +
J1004 1000052 Ø + + + +
J1004 1000053 Ø + + + +
J1004 1000054
10
7
Ø+ + + +
*1st sample – before bacterial contamination; **2nd sample – immediately after bacterial contamination; 
3rd sample – one hour after inactivation;
4th sample – day 3 after inactivation; 
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detectable levels (confirmed in two PC-P units at 3rd and/or
5th days).
Concerning the literature data, fresh PCs are contami-
nated with less than 100 bacteria per product 
1, 20. The num-
ber of inoculated bacteria can vary from low concentrations
(100–1,000 times higher than clinically relevant concentra-
tions) to high, when their number is approximately 10,000–
100,000 times bigger than in typical clinical conditions. In
our model, we achieved the degree of pathogen reduction
from 3–5 Log which represents an additional high-level
safety for patients receiving PCs. Impossibility to complete
inactivation of viable bacteria number in concentrations
 10
6 CFU per PC-P unit has no importance, because in
clinical practice we do not regularly see such a large number
of bacteria in fresh blood products. Finally, the obtained
degree of pathogen reduction/inactivation in our research
model was in accordance with the studies of other authors 
1, 4,
38, as well as the manufacturer's instructions.
The advantage of the Mirasol PRT system, unlike other
systems developed to inactivate pathogens in blood products,
is in the fact that after illumination of product with UV light
during 6–10 minutes (6.24 J / mL), these products are imme-
diately ready for clinical use. Therefore, there is no need for
subsequently removing RB and its metabolites from blood
products, since it is a vitamin, already present in the body of
the recipient.
Conclusion
In this study efficient pathogen inactivation (CFU de-
pletion) was obtained in investigated PC-P units – 3 Log for
all the three tested bacteria species and 5 Log for Escherichia
coli. Thus, the safety of blood component therapy – pre-
dominantly the clinical use of PCs – can be significantly im-
proved (lower morbidity/mortality rate) by using the Mirasol
PRT system.
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